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CONCLUSION:
COVID-19 infection in kidney transplant 
recipients
COVID 19 infection in kidney transplant patients can cause severe illness, 
requiring ITU admission with high rate of AKI
Prompt reduction in immunosuppression is required in severe cases
Older and diabetic patients may be at higher risk  Banerjee, 2020
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Outcome
48y 1989 Pred,AZA Home
67y 03/19 Diabetes Pred,Tac,MMF ITU, died
54y 12/19 Diabetes Pred,Tac,MMF ITU
65y 08/18 Pred,Tac,MMF ITU, ward
69y 02/20 Diabetes Pred,Tac,MMF ITU, ward
54y 05/13 Tac,MMF Home
45y 09/17 Pred,Tac,Aza Ward
SARS-CoV-2 a virus similar to SARS and 
MERS is causing a pandemic. We report 7 
cases of COVID 19 in kidney transplant 
recipients from South London , UK
- All presented with fever  & respiratory 
symptoms
- 2 patients were within 3 months of 
transplant
- Most treated with supportive care and 
reduced immunosuppression
- 4 needed ITU admission, 1 died
- High D dimer, ferritin, troponin levels 
and lymphopenia are seen in severe 
cases, are likely to be of prognostic 
value
- Extra pulmonary involvement 
contributes to mortality
Chest Xray for case 5
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Abstract 
By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected 
people from 177 countries and caused 11,252 reported deaths worldwide. Little is known 
about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney 
transplantation recipients, who may be at high-risk due to long-term immunosuppression, 
comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a 
respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown 
if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, 
we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 
45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a 
six-week period in three south London hospitals. Two of 32 patients presented within three 
months of transplantation. Overall, two were managed on an out-patient basis, but the 
remaining five required hospital admission, four in intensive care units. All patients displayed 
respiratory symptoms and fever. Other common clinical features included hypoxia, chest 
crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and 
troponin levels occurred in severe cases and likely prognostic. Immunosuppression was 
modified in six of seven patients. Three patients with severe disease were diabetic. During a 
three week follow up one patient recovered, and one patient died. Thus, our findings suggest 
COVID-19 infection in kidney transplant patients may be severe, requiring intensive care 
admission. The symptoms are predominantly respiratory and associated with fever. Most 
patients had their immunosuppression reduced and were treated with supportive therapy 
 
Key words: Kidney Transplantation, SARS-CoV-2 infection, COVID 19, immunosuppression  
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s 
Introduction 
The novel corona virus (2019-nCoV or COVID 19) infection, which originated in the city of Wuhan, in 
Hubei province, China in December 2019 shares close similarities in its genomic structure with the 
virus (SARS CoV) that caused the SARS global pandemic in 2003 and the MERS epidemic in 2012 
(MERS CoV), and even closer similarities to bat SARS-like betacoronavirus (bat-SL-CoVZC45 
betacoronavirus) and bat-SL-CoVZXC21. (1, 2)  
Between 31 December 2019 and 27 March 2020 532,692 COVID-19 cases and 24,077 deaths 
worldwide have been identified as being caused by a newly identified enveloped RNA virus named 
SARS-CoV-2.  (3)  In UK between 31 January 2020 and 20 March 2020 3,983 cases were identified 
with 177 (4% of tested patients) deaths. (4) Due to widespread nature, COVID 19 was declared as a 
pandemic by World Health Organisation  on 11 March 2020, and 176 countries are affected as of 27 
March 2020 (3).  
The SARS pandemic was reported to affect both paediatric and adult kidney transplant recipients in 
Hong Kong, with less severe disease in the paediatric population. (5) One liver transplant patient 
died with the SARS-Cov infection in 2003. (6) The MERS coronavirus infection had a variable impact 
on kidney transplant recipients. In one report of two kidney transplant patients, one died of 
progressive respiratory disease and acute kidney injury while the other survived. (7). To the best of 
our knowledge, only one patient with kidney transplantation has been reported in the literature who 
suffered from COVID 19 infection in Wuhan China and improved 13 days after hospital admission. (8) 
The 63-year-old kidney transplant recipient presented with fever, chest pain, cough, low 
lymphocyte, high serum C-reactive protein (CRP), and abnormal chest CT scan on 2 February 2020. 
Tacrolimus and mycophenolate administration was discontinued. He was treated with oxygen, 
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methyl prednisolone, umifenovir, moxifloxacin, biapenem, intravenous immunoglobulin, inhaled 
interferon α and pantoprazole. He made a successful recovery and was discharged on day 13.  
We report here the first seven cases of COVID-19 in kidney transplant recipients in south London 
hospitals.  
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Cases 
We have seen seven cases of kidney transplant recipients with proven COVID-19 infection in south 
London in March 2020. These patients are described below and main characteristics summarised in 
Tables 1 and 2. 
1. A 48-year-old man with deceased donor kidney transplant in 1989 with failing transplant kidney, 
(eGFR 15-18 ml/min/1.73m
2
) called in NHS (111) helpline in the first week of March 2020 with 
cough, fever and mild shortness of breath. He tested COVID-19 positive by nose and throat swabs 
taken on March 2. As he was clinically well, he was asked to stay at home and self-isolate. His 
immunosuppression was azathioprine 75 mg OD and prednisolone 5 mg OD which was not changed. 
He was not on ACEI/ARB at the time of presentation.  He has made a full recovery. The transplant 
kidney function remained stable. 
2. A 67-year-old woman with insulin-dependent type 2 diabetes and end stage kidney disease (ESKD) 
on haemodialysis therapy for four years received a deceased donor kidney transplant (DBD donor) in 
March 2019. Her estimated glomerular filtration rate (eGFR) was 45-55 ml/min/1.73m
2
. She was 
maintained on Tacrolimus with levels of between 5-8 ng/ml, Mycophenolate mofetil (MMF) 250 mg 
BD and prednisolone 5 mg OD. Her other medications included Ramipril, Aspirin, Alfacalcidol and 
Amiloride.   She presented on 5
th
 March  with cough, fever and shortness of breath. Chest X-ray 
revealed bilateral patchy consolidation (Fig 1A). SARS-CoV-2 RNA PCR tests from nose and throat 
viral swabs were positive. Bronchial washing for pneumocystis PCR was negative, as was blood PCR 
for CMV DNA. There was no other positive microbiological diagnosis.  She was hypoxic with 
peripheral oxygen saturation of 86% and a respiratory rate of 26/min, so she was transferred to 
intensive therapy unit (ITU) and commenced non-invasive ventilation (CPAP for type 1 respiratory 
failure) and subsequent intubation and ventilation as her clinical condition deteriorated. Serum CRP 
on admission was 83 mg/l, haemoglobin 110 g/l, with normal total white cell count and mild 
lymphopenia (lymphocyte count 0.8x10
9
/L).  She was treated with broad spectrum antibiotics. No 
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specific antiviral drugs were given. Mycophenolate mofetil (MMF) was ceased. Low dose tacrolimus 
was initially continued but stopped one day before death. On day 3 post admission, she developed 
AKI, with a serum creatinine increase to 225 µmol/l..  She remained stable on the ventilator with 
reducing oxygen requirements and improvement in lung infiltrates on chest X-ray (Fig 1B) but 
deteriorated markedly on 16
th
 March with high serum lactate and LDH levels and an acute rise of 
CRP to 190. She developed severe metabolic acidosis resistant to correction on CVVHDF, probably 
owing to an intra-abdominal event (bowel infarction/intra-abdominal sepsis). She deteriorated 
rapidly and died on 17
th
 March .  
3. A 54-year-old female with a history of adult polycystic kidney disease, ESKD in 2012, on 
haemodialysis for 7 years, received a deceased donor kidney transplant in December 2019. Soon 
thereafter, she experienced an episode of CMV infection and developed post-transplant diabetes 
mellitus (PTDM). Her medications included twice daily doses of tacrolimus 11 mg and MMF 500 mg, 
a once daily dose of prednisolone 5 mg, amlodipine 5 mg, aspirin 75 mg, bisoprolol 2.5 mg, co-
trimoxazole 480 mg, doxazosin 2 mg, isoniazid 300 mg, omeprazole 20 mg,  pyridoxine 25 mg, and 
gliclazide 120 mg and 80 mg daily. Three months after deceased donor kidney transplantation, on 
10
th
 March , she presented with shortness of breath to the emergency room. On initial assessment 
her oxygen saturations were 60% with heart rate of 105 beats/min and blood pressure of 190/99 
mmHg. She was started immediately on CPAP and her oxygen saturations improved to 87%. 
Auscultation of the chest revealed widespread crepitations and her CXR showed bilateral pulmonary 
infiltrates (Fig S1A). She was found to be positive for SARS-CoV-2 RNA. Her CMV, adenovirus and 
other respiratory viral screen along with atypical pneumonia serologies were negative. There was no 
other positive microbiological diagnosis. She developed features of acute respiratory distress 
syndrome (ARDS) and AKI (creatinine 242 µmol/L, baseline 132 µmol/L).. 
Her respiratory status rapidly deteriorated in the emergency room and she required intubation 8 
hours later and continues to be ventilated currently. MMF was stopped on 10
th
 March and 
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tacrolimus on 16
th
 March. Broad spectrum antibiotics and anti-viral, oseltamivir were administered. 
She was also empirically treated for pneumocystis with high dose co-trimoxazole. Serum CRP 
decreased from 329 mg/L on day of admission to 169 mg/L 7 days later. She became anuric and 
started CVVHF which continues. Her latest chest X-ray showed some resolution of the pulmonary 
infiltrates (Fig S1B). 
 4. A 65-year-old wheelchair-bound male, with a history of hypertensive nephrosclerosis and 
recurrent thromboembolic events developed ESRD in 2014 and received a deceased donor kidney 
transplant in August 2018.  Seventeen months after kidney transplantation, he presented to hospital 
with shortness of breath and chest pain and was admitted to ITU. He was diagnosed with COVID-19 
infection on 15
th
 March . MMF was stopped and he currently continues with tacrolimus and 
prednisolone. He was discharged from the ITU and is currently admitted to a medical ward still 
requiring 4-6 L oxygen to maintain saturations. Kidney function remained stable. 
5. A 69-year-woman with long standing diabetes and hypertension, ESKD, on peritoneal dialysis 
therapy since 2012 and hemodialysis therapy since 2014, received a deceased donor kidney 
transplantation on 29
th
 February and discharged on 9
th
 of March. Her immunosuppressive treatment 
included Tacrolimus, MMF and prednisolone. Other medications included insulin, amlodipine 10 mg, 
ezetimibe 10 mg, levothyroxine 150 mcg, co-trimoxazole 480 mg, as well as doxazosin 4 mg BD and 
clonazepam 1 mg prn.  She presented with shortness of breath, fever (39
0
C), diarrhoea and vomiting 
on 13
th
 March . Her chest X-ray showed shadowing of left base on 13
th
 March which worsened on 
19
th
 March (Fig S2A and Fig S2B). She tested positive for SARS-CoV-2 RNA on 14
th
 March 2020. She 
was unwell with oxygen saturation of 82%, blood pressure 166/52 mmHg. . Oxygen saturation 
improved to 97% with 4 L oxygen by nasal cannula. Haemoglobin was 74 g/L, serum NT-proBNP 5186 
ng/L, and serum fibrinogen 4.2 g/L.  Her lymphocyte count decreased on day 3 of admission to 
0.3x10
9
/L and has remained low. Tacrolimus was continued and MMF was held from 14
th
 March. She 
was treated initially with doxycycline, pipercillin/tazobactum, paracetamol, furosemide and blood 
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transfusion. She was moved to ITU on 15
th
 March for respiratory support but did not need more than 
5 L/min oxygen and transferred back to ward on the 17
th
 March. On 20
th
 March her serum creatinine 
was 138 µmol/L.  She remains an in-patient and is being managed in general ward.  
6. A 54-year-old man with urate nephropathy and past history of hereditary haemolytic anaemia, 
received a kidney transplant 7 years ago. He presented on 10
th
 March with cough and fever (38.5°C) 
and tested positive for SARS-CoV-2 RNA on 13
th
 March. He was adequately hydrated and vitals were 
stable. He received paracetamol and continued his usual medications including  advagraf 3.5 mg OD ,  
MMF 500 mg BD, nifedipine 30 mg OD, atorvastatin 30 mg at night, bisoprolol 10 mg OD, Ramipril 10 
mg OD, Doxazosin 8 mg BD, alfacalcidol 1 mcg OD, and penicillin 250 mg OD. He developed AKI with 
a rise in creatinine from 145 µmol/L to 187 µmol/L. Haemoglobin was 141 g/L Blood cell counts are 
shown in Table 2. He remained symptomatic on 21
th
 March  with cough and mild fever. As the 
symptoms were not resolving, MMF was stopped and he has managed to stay at home. 
7. A 45-year-old man with a failing, second kidney transplant from September 2017 presented with 
fever, flu-like symptoms and cough for 7 days and shortness of breath for 1 day. He had arterial 
hypertension with no other comorbidities. He was a sensitised recipient Panel Reactive Antibody 
90%) and therefore, was maintained on long-term triple immunosuppression: tacrolimus, 
azathioprine (switched in late 2018 from MMF due to gastrointestinal side effects) and prednisolone 
10 mg OD. On admission on 17
th
 March , he was tachypnoeic and hypoxic with oxygen saturation of 
90% on room air, corrected to >95% on 4 L/min oxygen through nasal cannula. Nasal and throat 
swabs were positive for SARS-CoV-2 RNA. He developed AKI with serum creatinine 967 µmol/L and 
eGFR 5 ml/min/1.73 m2 (baseline creatinine 400-450, eGFR 12-16). He was lymphopenic with 
lymphocyte count of 0.3 x10
9
/L (baseline 1-1.2 x10
9
/L) with normal haemoglobin and white cell 
count. Liver function tests were normal on admission but ALT went up to 138 U/L on days 4.. Chest 
X-ray revealed bilateral infiltrates (Fig S3). Azathioprine was stopped on admission, tacrolimus 
reduced and prednisolone increased to 15 mg OD. He needed so far one hemodialysis session.  He is 
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recovering from respiratory point of view and as of 23
st
 March 2020, the oxygen saturations are 
>95% on 2 L/min. He remains haemodynamically stable. 
Discussion 
In this report we discuss our first 7 cases of COVID 19 infection in kidney transplant recipients from 
south London, UK. Median age of transplant recipients was 54 years (range 45-69y) comprising 4 
males, 3 females. Out of 7 patients, 2 were managed on an out-patient basis and stayed at home, 
with the remaining 5 (71%) requiring hospital admission. Four among the latter required ITU 
admission and one is being managed in the renal ward. Out of four patients sent to ITU, two needed 
intubation and ventilation; the other two were managed with oxygen through mask and non-
invasive ventilation only. There was one death in this small series of 7 patients (mortality rate of 
14%). All 3 patients with severe disease were females and also had diabetes. Two patients presented 
within 3 months of kidney transplantation (one within 2 weeks) while kidney transplant vintage was 
12 months or more in the remaining five cases. The patients were managed in three centres and the 
total number of prevalent transplant patients in these centres was 2082, with 32 patients 
transplanted from 15
th
 December 2019 to 15
th
 March 2020 during the developing pandemic.  
Transplant patients are at higher risk due to immunosuppression, underlying CKD and other co-
morbidities, in particular diabetes and hypertension which are now recognised as significant factors 
that influence outcomes in patients with COVID 19 infection. (9) Three of our patients had CKD stage 
4-5 with one recovering at home and one requiring hospital admission but recovering without 
needing ITU admission. The remaining 4 patients had CKD stage 3 of which two had severe disease 
requiring intubation and ventilation and one of them died. Both patients who had severe COVID-19 
including the one who died had diabetes mellitus.  
Managing immunosuppression in these patients is challenging and this should take in to account age 
of, severity of COVID 19 infection, associated co-morbidities and time post-transplant. In transplant 
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patients with mild to moderate infections, usual practice is to continue or make reductions in the 
dose of immunosuppressive drugs but this approach might favour high mortality in patients 
admitted to hospital with COVID-19 infection. Whilst we acknowledge that firm recommendations 
are not possible based on the small sample size of this study, we suggest that anti-proliferative 
agents (mycophenolate mofetil/azathioprine) should be stopped at the time of admission to 
hospital, dose of prednisolone either unchanged or increased, and tacrolimus dose reduced. In 
severe infections (requiring intubation and ventilation), an argument can be made for stopping 
calcineurin inhibitors completely while maintaining corticosteroid therapy. The role of cytokine 
storm and inflammation due to anti-viral immune response as a driver of severe respiratory disease 
and ARDS has been discussed since the outbreak of this disease in December 2019, prompting trials 
of anti-interleukin 6 monoclonal antibody tocilizumab and case for continuing steroids in infected 
patients. Similar argument can be made for continuing low dose tacrolimus but more evidence is 
needed before drawing firm conclusions. An obvious concern is risk of rejection with reduction in 
immunosuppression but given the high mortality rate of COVID-19 infection in hospitalised patients, 
clinicians should focus on keeping their patients alive with a careful case by case assessment of risks 
versus benefits of continuing immunosuppression. With regards to induction treatment, it is likely 
that lymphocyte depleting antibodies increase the risk and therefore, many centres in the UK have 
stopped performing transplants requiring induction with either ATG or alemtuzumab. All patients in 
this series received basiliximab induction therapy at time of transplantations. Five of the 7 patients 
presented here were receiving triple immunosuppression. Two patients with mild illness who did not 
require hospital admission and recovered fully at home were on dual immunosuppression (one on 
azathioprine/ prednisolone and one on tacrolimus/MMF).  
With regard to concomitant therapy with ACEI/ARBs, in line with current UK Renal Association and 
European Society of Cardiology recommendations, these therapies were not discontinued.  
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One out of our 7 patients died (a mortality rate of 14%) although it is too soon to comment on likely 
mortality rates in this group of patients.  Two of our patients presented within 3 months after 
transplantation and one presented within 2 weeks. UK NHSBT/ODT have since produced guidelines 
on COVID-19 screening in deceased donors and the transplant units are risk stratifying donors and 
recipients before considering kidney transplantation. Transplantation is a high-risk procedure during 
this pandemic due to the risk of transmitting COVID-19 infection from the donor to the recipient as 
well as risk of recipient developing severe disease under higher levels of immunosuppression in the 
first 3 months post transplant. We suggest that apart from carefully selecting donor-recipient pairs, 
transplantation is not advisable during this pandemic, especially for older recipients with co-
morbidities, in particular diabetes. We have stopped performing living donor transplants and are in 
discussions to suspend deceased donor programme. In addition to  significant concerns about the 
effect of COVID-19 on immunosuppressed patients, increasing worries about access to ITU in the 
coming weeks and re-distribution of staff to critical care to provide support for increasing number of 
COVID-19 patients, it is likely that deceased donor programme will be suspended within most of the 
UK centres soon.  
AKI has been described with COVID-19 infections in up to 15% patients, and occurrence of 
proteinuria /hematuria has been reported. In our series, the observation that 4/7 patients had AKI 
(57%) may be an early signal that transplant patients are at higher risk of AKI with COVID-19 
infection, compared to 29% AKI in critically ill patients of general population in Wuhan, China. (11) 
ACE2 and dipeptidyl peptidase (DPP4), which are expressed in proximal tubule cells, (12, 13) have 
been identified as receptors for SARS-CoV and MERS-CoV. Uptake of SARS-CoV-2 virus into the 
proximal tubular epithelium is a possible explanation for AKI.  
With regards to prognostic blood tests including lymphocyte counts and serum levels of D dimer, 
ferritin and troponin are likely to be valuable. Four out of five patients who required admission had 
lymphopenia, whereas the two who did not need admission had normal lymphocyte counts. As 
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many patients on immunosuppression are likely to have baseline lymphopenia, further drop in 
lymphocyte count is likely to be of prognostic value. In our patient who died, both D dimer and 
troponin levels were elevated on day 3 post admission with further marked increase (in particular D 
dimer) later during the course of her illness. In the absence of any obvious thromboembolic events, 
this suggests microvascular thrombosis or DIC with possible gut ischaemia. Very high ferritin and D 
dimer levels were also noted in case 7 of our series. We suggest that D dimer, ferritin and troponin 
should be measured in all patients with severe COVID-19 infection on admission and subsequently in 
those who are not showing clinical improvement. 
In two of our patients, the lung infiltrates showed significant improvement without any specific anti-
viral treatment 7-9 days post admission. The patient who died is one of them and was improving 
from the respiratory point of view. She died of an abdominal complication and the clinical diagnosis 
was possible bowel infarction or intra-abdominal sepsis. Based on this observation we would like to 
highlight that the mortality in critically ill patients with COVID-19 infection could be due to extra-
pulmonary complications such as myocarditis or bowel involvement.  
With regards to specific anti-viral therapies, although a recent trial showed no benefit of lopinavir-
ritonavir in hospitalized patients with severe COVID-19, it remains possible that treatment with 
these drugs as well as hydroxychloroquine will be considered in patients with COVID-19 pneumonia. 
(14)  The choice of calcineurin inhibitor may also have a role to play. Thus for instance cyclosporin A 
has been shown to have an inhibitory effect on proliferation of corona viruses and hepatitis C virus 
in vitro, while this is not the case for tacrolimus. Cyclosporin A is thought to inhibit the replication of 
a diverse array of coronaviruses through its impact on cyclophilin A and B. (15, 16) Whilst this needs 
further exploration, we do not think switching to cyclosporine A from tacrolimus can be 
recommended at this stage for transplant patients with COVID-19 infection. 
In conclusion, in this first series of 7 renal transplant patients infected with SARS-CoV-2 virus, one 
recipient died (14%) and significant AKI was observed.  Lymphopenia, very high ferritin and D dimer 
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levels and raised troponin levels are seen in severe disease and may  be of prognostic value. These 
tests should be part of routine testing in kidney transplant patients requiring hospital admission for 
COVID-19 infection. We suggest suspending kidney transplantation during the COVID-19 pandemic 
particularly for high risk older recipients with comorbidities.  Rigorous adherence to hand hygiene, 
recommended isolation procedures and regular virtual/telephonic assessment of transplant patients 
will help reduce the incidence and facilitate management of mild to moderate cases in the 
community as we could in two of our 7 patients described. 
The COVID-19 UK register has been set up by UK transplant registry held by ODT to record all cases 
of renal transplant patients presenting with COVID-19 infection and analysis of registry data will help 
clinicians make informed decisions about management of these complex patients in these uncertain 
and rapidly evolving times.  
Figure 1:  Case2: CxR on admission(1A) showing bilateral patchy consolidation and 8 days later  
showing improvement in lung infiltrates (1B) 
Supplementary Material 
Supplementary Figure 1: Case3: CxR on admission(S1A) showing bilateral patchy consolidation and 9 
days later showing improvement in lung infiltrates (S1B) 
Supplementary Figure 2: Case5: CxR on admission(S2A) showing left basal shadow worsening to B/L 
patchy consolidation 6 days later (S2B) 
Supplementary Figure 3: Case7: CxR on admission showing bilateral lung infiltrates 
Supplementary information is available on Kidney International’s web site. 
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Table 1 Clinical characteristics and outcome of seven kidney transplant patients with COVID 19 infection 
 Age/
Sex 
Tx 
date 
Co-
morbidities 
Respiratory and renal 
involvement 
Baseline 
creatinine  
(eGFR 
ml/min/1.73
m
2
) 
Baseline 
Immunosuppression and 
treatment 
ACEi 
or 
ARB 
Outcome 
1 48/
M 
1989 HT No 350 (15-18) Aza/Pred- No change N Stayed at home, full recovery 
2 67/F 03/20
19 
T2D/HT Yes, ARDS + AKI(CVVH) 150(45) Tac/MMF/Pred- MMF 
stopped 
Y ACEi Died  
3 54/F 12/20
19 
PTDM/ 
CMV 
Yes, ARDS+AKI 
(CVVH) 
132(48) Tac/MMF/Pred-  
Tac and MMF stopped 
N Alive, Ventilated 
4 65/
M 
08/20
18 
Wheelchair/
HTN 
No ARDS 180 (23) Tac/MMF/Pred 
MMF stopped 
N Alive, in medical ward 
5 69 /F 02/20
20 
DM/HT No ARDS 
AKI 
165 (31) Tac/MMF/Pred 
MMF stopped 
N Brief ITU stay, not intubated 
stepped down to ward 
6 54 
/M 
05/20
13 
Haemolytic 
anaemia/HT 
No ARDS 187(47) Tac/MMF 
MMF stopped 
N Stayed at home, still has 
some cough and flu like 
symptoms 
7 45 
/M 
09/20
17 
(2
nd
 
Tx) 
HT No ARDS 
AKI(HD) 
450 (12-16) Tac/Aza/Aza 
Aza stopped 
Tac dose reduced 
N Admitted, managed in the 
ward. Severe AKI 
Legend: Yr=year, M=male, F=female, Y=yes, N=No, Aza=azathioprine, MMF=mycophenolate mofetil, ITU=intensive therapy unit, NIV=non-invasive 
ventilation, CVVH-continuous veno-venous haemofiltration, AKI-Acute Kidney injury, ARDS-Acute Respiratory Distress Syndrome). 
Table 2: Blood parameters during COVID-19 infection 
Case  White cell 
count  
(x10
9
/L) 
(3.5-10) 
Lympho
cyte 
count 
(x10
9
/L) 
(1-3.5) 
Serum 
CRP 
(mg/L) 
(<5) 
Serum 
ferritin  
(µg/L) 
(25-
200) 
Serum D 
Dimer 
(µg/L) 
(0-500) 
Serum 
LDH 
(U/L) 
(100-
240) 
Serum 
troponin I 
(ng/L) 
(<34) 
1        
2 6(D1) 0.8(D1) 83 
(D1) 
 2032 
(D3), 
>6000 
(D10) 
1226 
(D10) 
78(D1),  
395 (D10) 
3 11.25(D1) 0.5(D1) 329 
(D1) 
    
4        
5 9.4(D1) 0.3(D1)     *30 (D4) 
6 10(D1) 4.0(D1)      
7 5.5(D1) 0.3(D1) 198 
(D1) 
6919 
(D3) 
1907 
(D3) 
502 
(D3) 
35 
(D7) 
CRP- C-reactive protein, LDH- Lactate Dehydrogenase 
*Serum troponin T (0-14ng/l) 
D=day after admission and D1 is day of admission 
 


